In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases

Yee Huang Ku, Mei Feng Lee, Yin Ching Chuang, Chi Chung Chen, Wen Liang Yu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The widespread multidrug-resistant Enterobacteriaceae pose a serious therapeutic challenge. Colistin and tigecycline are potential antimicrobial agents for treating infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. We evaluated the in-vitro activity of colistin sulfate against 253 ESBL producers isolated from patients admitted to a medical center in southern Taiwan (Escherichia coli, n = 82; Klebsiella pneumoniae, n = 102; Enterobacter cloacae, n = 34; and Serratia marcescens, n = 35). Colistin showed promising in-vitro activity against E. coli, K. pneumoniae, and E. cloacae, but not S. marcescens. One ESBL-producing K. pneumoniae strain with resistance to carbapenems (ertapenem, imipenem, and meropenem) was selected for time-killing studies. A combination of colistin and tigecycline showed synergism, but there was an inoculum effect. In conclusion, colistin was active against most ESBL-producing Enterobacteriaceae, and a combination of colistin with tigecycline was synergistic against some highly resistant strains, even those with carbapenem resistance.

Original languageEnglish
Pages (from-to)699-702
Number of pages4
JournalJournal of Microbiology, Immunology and Infection
Volume48
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Colistin
Enterobacteriaceae
Klebsiella pneumoniae
Enterobacter cloacae
Serratia marcescens
Carbapenems
meropenem
Escherichia coli
Imipenem
Anti-Infective Agents
Taiwan
In Vitro Techniques
Infection
tigecycline

Keywords

  • Colistin
  • Enterobacteriaceae
  • ESBL
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Infectious Diseases

Cite this

In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases. / Ku, Yee Huang; Lee, Mei Feng; Chuang, Yin Ching; Chen, Chi Chung; Yu, Wen Liang.

In: Journal of Microbiology, Immunology and Infection, Vol. 48, No. 6, 01.12.2015, p. 699-702.

Research output: Contribution to journalArticle

Ku, Yee Huang ; Lee, Mei Feng ; Chuang, Yin Ching ; Chen, Chi Chung ; Yu, Wen Liang. / In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases. In: Journal of Microbiology, Immunology and Infection. 2015 ; Vol. 48, No. 6. pp. 699-702.
@article{92ddac05efb248c4b4306614682740ed,
title = "In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases",
abstract = "The widespread multidrug-resistant Enterobacteriaceae pose a serious therapeutic challenge. Colistin and tigecycline are potential antimicrobial agents for treating infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. We evaluated the in-vitro activity of colistin sulfate against 253 ESBL producers isolated from patients admitted to a medical center in southern Taiwan (Escherichia coli, n = 82; Klebsiella pneumoniae, n = 102; Enterobacter cloacae, n = 34; and Serratia marcescens, n = 35). Colistin showed promising in-vitro activity against E. coli, K. pneumoniae, and E. cloacae, but not S. marcescens. One ESBL-producing K. pneumoniae strain with resistance to carbapenems (ertapenem, imipenem, and meropenem) was selected for time-killing studies. A combination of colistin and tigecycline showed synergism, but there was an inoculum effect. In conclusion, colistin was active against most ESBL-producing Enterobacteriaceae, and a combination of colistin with tigecycline was synergistic against some highly resistant strains, even those with carbapenem resistance.",
keywords = "Colistin, Enterobacteriaceae, ESBL, Tigecycline",
author = "Ku, {Yee Huang} and Lee, {Mei Feng} and Chuang, {Yin Ching} and Chen, {Chi Chung} and Yu, {Wen Liang}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.jmii.2013.11.005",
language = "English",
volume = "48",
pages = "699--702",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases

AU - Ku, Yee Huang

AU - Lee, Mei Feng

AU - Chuang, Yin Ching

AU - Chen, Chi Chung

AU - Yu, Wen Liang

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The widespread multidrug-resistant Enterobacteriaceae pose a serious therapeutic challenge. Colistin and tigecycline are potential antimicrobial agents for treating infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. We evaluated the in-vitro activity of colistin sulfate against 253 ESBL producers isolated from patients admitted to a medical center in southern Taiwan (Escherichia coli, n = 82; Klebsiella pneumoniae, n = 102; Enterobacter cloacae, n = 34; and Serratia marcescens, n = 35). Colistin showed promising in-vitro activity against E. coli, K. pneumoniae, and E. cloacae, but not S. marcescens. One ESBL-producing K. pneumoniae strain with resistance to carbapenems (ertapenem, imipenem, and meropenem) was selected for time-killing studies. A combination of colistin and tigecycline showed synergism, but there was an inoculum effect. In conclusion, colistin was active against most ESBL-producing Enterobacteriaceae, and a combination of colistin with tigecycline was synergistic against some highly resistant strains, even those with carbapenem resistance.

AB - The widespread multidrug-resistant Enterobacteriaceae pose a serious therapeutic challenge. Colistin and tigecycline are potential antimicrobial agents for treating infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. We evaluated the in-vitro activity of colistin sulfate against 253 ESBL producers isolated from patients admitted to a medical center in southern Taiwan (Escherichia coli, n = 82; Klebsiella pneumoniae, n = 102; Enterobacter cloacae, n = 34; and Serratia marcescens, n = 35). Colistin showed promising in-vitro activity against E. coli, K. pneumoniae, and E. cloacae, but not S. marcescens. One ESBL-producing K. pneumoniae strain with resistance to carbapenems (ertapenem, imipenem, and meropenem) was selected for time-killing studies. A combination of colistin and tigecycline showed synergism, but there was an inoculum effect. In conclusion, colistin was active against most ESBL-producing Enterobacteriaceae, and a combination of colistin with tigecycline was synergistic against some highly resistant strains, even those with carbapenem resistance.

KW - Colistin

KW - Enterobacteriaceae

KW - ESBL

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=84952870818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952870818&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2013.11.005

DO - 10.1016/j.jmii.2013.11.005

M3 - Article

C2 - 24388585

AN - SCOPUS:84952870818

VL - 48

SP - 699

EP - 702

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 6

ER -